Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Hypertrophic obstructive cardiomyopathy

Hypertrophic obstructive cardiomyopathy

Part of Cardiomyopathy

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hypertrophic obstructive cardiomyopathy

5 trials tracked for Hypertrophic obstructive cardiomyopathy: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 112 citations.

5Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 3 Phase 2 1 Other / NA 1
  1. Phase 3 A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM Completed · 112 cited
  2. Phase 3 Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Completed · 101 cited
  3. Phase 3 A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy Completed
  4. Phase 2 A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction Completed
  5. N/A Advancing Understanding of Transportation Options Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Hypertrophic obstructive cardiomyopathy: what the trials found

Mavacamten has demonstrated efficacy in reducing LVOT peak gradients in patients with hypertrophic obstructive cardiomyopathy. At week 30, a significant proportion of participants achieved a Valsalva LVOT peak gradient of < 30 mmHg 1 and < 50 mmHg 1.

Clinical improvements associated with mavacamten include a measurable reduction in the severity of HCM symptoms as measured by the HCMSQ score 2 and an improvement in health-related quality of life (KCCQ score) at week 30 2. Additionally, approximately 63.2% of patients treated with mavacamten showed at least one class improvement in their New York Heart Association (NYHA) functional class by week 30 3.

Recent results — preliminary, needs further review

  • MYK-461 showed a reduction in dyspnea symptom scores from baseline to week 12, with some participants achieving a post-exercise peak LVOT gradient of < 30 mmHg 4.
  • A driving decision aid was evaluated for older adults, showing improvements in values clarity and safety knowledge scores 5.

For the clinician treating this condition

  • Mavacamten is associated with significant reductions in LVOT peak gradients at week 30 1.
  • Mavacamten treatment correlates with improved patient-reported quality of life (KCCQ) and reduced symptom severity (HCMSQ) 2.
  • A majority of patients treated with mavacamten experienced an improvement in NYHA functional class by week 30 3.

AI synthesis of 5 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review and meta-analysis of MYH7 versus MYBPC3 variants in obstructive hypertrophic cardiomyopathy
Cardiology Meta-analysis
Systematic review and meta-analysis of MYH7 versus MYBPC3 variants in obstructive hypertrophic cardiomyopathy Specific heart genes predict different risks for HCM patients
This systematic review and meta-analysis pooled data from 192,361 participants in cohort or registry studies to compare MYH7 and MYBPC3 vari…
New data shows specific heart genes predict different risks for people with obstructive hypertrophic cardiomyopathy and guide care plans.
Frontiers Apr 29, 2026
Thyroid dysfunction and atrial fibrillation risk in hypertrophic obstructive cardiomyopathy patients
Diabetes & Endocrinology Cohort
Thyroid dysfunction and atrial fibrillation risk in hypertrophic obstructive cardiomyopathy patients Thyroid Levels May Predict Heart Rhythm Problems in a Common Heart Condition
This observational cohort study of 755 HOCM patients examined the association between thyroid dysfunction and atrial fibrillation risk.
Monitoring thyroid function could become a simple way to help identify and manage heart rhythm risks in patients with a specific heart muscl…
Frontiers Apr 22, 2026

Research across Cardiomyopathy

Related studies from across the Cardiomyopathy family.

Cardiac myosin inhibitors improve exercise capacity and health status in patients with hypertrophic cardiomyopathy
Cardiology Meta-analysis
Cardiac myosin inhibitors improve exercise capacity and health status in patients with hypertrophic cardiomyopathy New heart medication shows promise for hypertrophic cardiomyopathy patients
This meta-analysis evaluated the impact of cardiac myosin inhibitors on adults with symptomatic non-obstructive hypertrophic cardiomyopathy.…
A new class of heart drugs may improve exercise capacity and quality of life for people with a specific heart muscle condition.
medRxiv Sep 12, 2026
AI-empowered echocardiography shows promise for HCM diagnosis and risk prediction, but validation is lacking
Cardiology Sys. Review
AI-empowered echocardiography shows promise for HCM diagnosis and risk prediction, but validation is lacking AI Echocardiography Shows Promise for Heart Condition
This systematic review synthesizes AI-empowered echocardiography applications in hypertrophic cardiomyopathy, categorizing methods by comple…
AI-powered echocardiography may improve diagnosis and risk prediction for hypertrophic cardiomyopathy, but large-scale validation is still n…
Frontiers Aug 27, 2026
Transthyretin stabilizers and RNA-silencing therapies attenuate cardiac remodeling in transthyretin amyloid cardiomyopathy
Cardiology Meta-analysis
Transthyretin stabilizers and RNA-silencing therapies attenuate cardiac remodeling in transthyretin amyloid cardiomyopathy New Therapies May Slow Heart Damage in Amyloid Cardiomyopathy
This meta-analysis of 3646 adults with cardiac amyloidosis found that transthyretin stabilizers and RNA-silencing therapies are associated w…
Specific drug therapies may help stabilize heart structure and slow the progression of damage for adults with transthyretin amyloid cardiomy…
medRxiv Aug 11, 2026
Gene, inflammation, and metabolic dysregulation drive pathophysiology in pediatric dilated cardiomyopathy
Cardiology Sys. Review
Gene, inflammation, and metabolic dysregulation drive pathophysiology in pediatric dilated cardiomyopathy Gene, Inflammation, Metabolism Link in Child Heart Failure
This systematic review examines the role of the gene-inflammation-metabolism axis in pediatric dilated cardiomyopathy. The authors identify …
A new review links genes, inflammation, and metabolism in pediatric dilated cardiomyopathy, offering a roadmap for targeted treatments.
Frontiers Aug 9, 2026
Supraventricular tachyarrhythmias occur more frequently in patients with Arrhythmogenic Cardiomyopathy and Brugada Syndrome
Cardiology Meta-analysis
Supraventricular tachyarrhythmias occur more frequently in patients with Arrhythmogenic Cardiomyopathy and Brugada Syndrome Heart conditions like Brugada syndrome increase risk of rapid heartbeats
This systematic review of 30 studies indicates that supraventricular tachyarrhythmias (SVT) are more frequent in patients with Arrhythmogeni…
Patients with certain heart conditions face a higher risk of fast heartbeats, which can lead to complications like heart failure or unnecess…
Frontiers Jul 30, 2026
Exercise improves cardiorespiratory fitness and quality of life in patients with hypertrophic cardiomyopathy
Physical Medicine & Rehab Meta-analysis
Exercise improves cardiorespiratory fitness and quality of life in patients with hypertrophic cardiomyopathy Exercise improves heart health and fitness for HCM patients
This meta-analysis of 9,702 patients with hypertrophic cardiomyopathy (HCM) found that exercise is associated with increased peak oxygen con…
New research shows that structured exercise can improve heart fitness, body weight, and quality of life for people with hypertrophic cardiom…
Jul 25, 2026
Global Longitudinal Strain as a Potential Predictor of Sudden Cardiac Death in Hypertrophic Cardiomyopathy
Radiology & Imaging Meta-analysis
Global Longitudinal Strain as a Potential Predictor of Sudden Cardiac Death in Hypertrophic Cardiomyopathy Heart imaging helps identify high risk in cardiomyopathy patients
Meta-analysis suggests reduced global longitudinal strain identifies high-risk patients with hypertrophic cardiomyopathy prone to fatal arrh…
A new way to measure heart muscle movement may help doctors identify which patients with a specific heart condition are at higher risk for s…
Jul 6, 2026
Vascular smooth muscle cell immune interactions drive remodeling across cardiovascular diseases
Oncology Sys. Review
Vascular smooth muscle cell immune interactions drive remodeling across cardiovascular diseases How blood vessel cells drive heart disease and high blood pressure
This narrative review synthesizes mechanisms of VSMC-immune interactions in atherosclerosis, hypertension, aortic aneurysms, and arteritis. …
A new review reveals how blood vessel cells change in heart disease, high blood pressure, and more.
Frontiers Jun 7, 2026
Review of Diabetic Cardiomyopathy without reported trial data or specific outcomes
Cardiology Sys. Review
Review of Diabetic Cardiomyopathy without reported trial data or specific outcomes Review of Diabetic Cardiomyopathy offers new understanding of this heart condition
This narrative review addresses Diabetic cardiomyopathy but reports no specific population, sample size, or intervention details. The author…
This review looks at diabetic cardiomyopathy to help doctors understand this specific heart problem better for patients with diabetes.
Frontiers Jun 4, 2026
Mini review examines sudden cardiac death risks in marathon runners across different age groups
Cardiology Sys. Review
Mini review examines sudden cardiac death risks in marathon runners across different age groups Marathon running links to higher heart risk in older men and full-distance participants
This mini review synthesizes evidence on sudden cardiac death (SCD) and coronary artery disease in marathon runners. The authors note that r…
A review of marathon runners shows heart risks vary by age, sex, and race distance, with most events happening near the finish.
Frontiers May 28, 2026
Narrative review discusses Ganoderma lucidum polysaccharides for diabetes and related complications
Diabetes & Endocrinology Sys. Review
Narrative review discusses Ganoderma lucidum polysaccharides for diabetes and related complications New research shows mushroom compounds may help control blood sugar and fix organ damage
This narrative review examines the theoretical potential of Ganoderma lucidum polysaccharides (GLPs) for diabetes and associated conditions.
A common mushroom extract could help lower blood sugar and heal organ damage for millions of people with diabetes
Frontiers May 1, 2026
Deep learning model screens for transthyretin amyloid cardiomyopathy using ECG images
Cardiology Cohort
Deep learning model screens for transthyretin amyloid cardiomyopathy using ECG images AI spots hidden heart disease from routine ECGs
This observational study developed a deep learning model to identify transthyretin amyloid cardiomyopathy from ECG images.
A new AI tool finds signs of a dangerous heart disease in routine ECGs years before symptoms worsen, offering hope for earlier treatment in …
medRxiv Apr 30, 2026